جست‌وجوی استاد و پژوهشگر

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +۵ مورد دیگر

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

• Pharmacoepidemiology
• Drug Safety
• Diabetes Mellitus
• +۳ مورد دیگر

Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.

• Longitudinal Data Analysis
• Time-to-Event Analysis
• Survival Analysis
• +۵ مورد دیگر

Alessandra Meddis serves as an Assistant Professor in the Section of Biostatistics within the Department of Public Health at the University of Copenhagen's Faculty of Health and Medical Sciences. Her academic work centers on developing and applying advanced statistical methodologies for longitudinal and time-to-event data analysis, with significant contributions to public health research in Denmark and internationally. Her institutional affiliation is clearly established through university contact details and departmental listings. Her primary research interests include correlated survival data analysis, competing risk modeling, informative cluster size methodology, causal inference techniques for observational studies, and environmental epidemiology applications. Dr. Meddis has developed specialized expertise in handling complex survival data structures while maintaining focus on real-world public health problems, particularly in HIV comorbidity patterns, environmental exposure effects, and pandemic-related mortality analyses. Her methodological innovations directly address challenges in clustered and censored data common across medical research domains. Analysis of Dr. Meddis's recent publication record reveals a consistent trajectory of high-impact interdisciplinary research spanning clinical medicine, epidemiology, and statistical methodology. Her work appears in leading journals across biostatistics, infectious diseases, and public health, demonstrating strong collaborative networks with clinical researchers and epidemiologists. Key thematic areas include HIV treatment outcomes, environmental health exposures, and critical care applications during the pandemic, with recent methodological papers advancing survival analysis techniques for complex data structures. Scientific Awards: No scientific awards were specified in the available institutional profile. Advising and Grants: The institutional profile does not provide details regarding graduate student supervision or specific research grant funding. Her collaborative publications suggest involvement in multi-investigator projects including the COCOMO HIV cohort study and pandemic-related research initiatives. Labs and Teams: Dr. Meddis is affiliated with the Section of Biostatistics within the Department of Public Health, though specific laboratory facilities or dedicated research teams are not described in the source material. Her extensive co-authorship patterns indicate active participation in multiple research consortia across medical specialties.

• Nuclear Magnetic Resonance (NMR)
• In vivo imaging
• MRI pulse sequence development
• +۷ مورد دیگر

Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.

• Statistical Methods in Biomedical Research
• Biomarker Analysis
• Clinical Trial Design
• +۷ مورد دیگر

Todd A. Alonzo is a Professor of Research in the Department of Preventive Medicine at the University of Southern California . As Group Statistician for the Children's Oncology Group , he focuses on statistical methods for biomarker analysis, medical diagnostic testing, and clinical trial design in pediatric acute myeloid leukemia (AML). Education: B.S. in Statistics, California State Polytechnic University (1994) MS and PhD in Biostatistics, University of Washington (1997, 2000) Research Interests include: Development of statistical frameworks for diagnostic accuracy Genomic and proteomic profiling in AML Pharmacogenomic score systems for chemotherapy response Non-inferiority trial design in low-event-rate settings Health disparities in pediatric oncology Scientific Awards : Fellow, American Statistical Association (2018) Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine (2017) NIH Predoctoral Cardiovascular Biostatistics Training Grant (1995) ENAR Biometrics Society Distinguished Student Paper Award (1999) WNAR Biometrics Society Best Student Oral Presentation (1999) Leadership & Service includes editorial board memberships (Biometrics, Pediatric Blood & Cancer, Biometrical Journal), reviewer for 30+ scientific journals, and roles on multiple Data Safety and Monitoring Boards. He served as President of the International Biometric Society Western Northern America Region (WNAR) in 2009.

• Multiple Myeloma
• Lymphoma
• Thalassemia
• +۵ مورد دیگر

Professor Joy Ho is a Clinical Professor of Medicine at the University of Sydney’s Central Clinical School and a Senior Staff Specialist in Haematology at Royal Prince Alfred Hospital (RPAH). She serves as Director of Research and Head of the Multiple Myeloma Research Unit and Thalassemia/Haemoglobinopathy Unit at the Institute of Haematology, RPAH. Her research focuses on multiple myeloma, lymphoma, thalassemia, and iron metabolism, with a strong emphasis on clinical trials and translational medicine. She has led numerous multi-centre trials, including pioneering studies on CAR-T cell therapy for lymphoma and novel therapies for myeloma. Prof Ho’s education includes MB.BS. (Hons) from Sydney, D.Phil (Oxford), and fellowships from the Royal Australasian College of Physicians (RACP) and Royal College of Pathologists of Australasia (RCPA). She has held leadership roles in major hematology organizations, including the International Myeloma Working Group (IMWG) and the American Society of Hematology (ASH). Her international collaborations span Singapore, Thailand, and the United States. Her research interests include: Multiple Myeloma: Developing therapies targeting tumor microenvironment and immune modulation. Lymphoma: Pioneering CAR-T cell therapy in Australia. Thalassemia: Gene therapy and iron chelation advancements, including the landmark Northstar trial. Iron Metabolism: Investigating hepcidin and its role in transfusion-dependent anemias. Her recent publications highlight breakthroughs in CAR-T efficacy, myeloma biomarkers, and thalassemia management. Awards include the 2019 Sydney Local Health District Clinical Trial Award and election to the International Myeloma Society Board. She has secured over $2 million in grants for cutting-edge equipment and research. Prof Ho’s academic contributions extend to teaching and supervision, training fellows for RACP/RCPA certifications. Her leadership in national registries (e.g., Australian Haemoglobinopathy Registry) and guidelines (e.g., iron chelation protocols) underscores her commitment to advancing hematology care globally.

Iona Chengمشاهده پروفایل

استاد

• Cancer Epidemiology
• Genetic Epidemiology
• Racial/Ethnic Differences in Cancer Risk
• +۵ مورد دیگر

Iona Cheng is a Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), where she conducts groundbreaking research in cancer epidemiology. She serves as co-Investigator of the SEER Greater Bay Area Cancer Registry and is Principal Investigator of multiple NIH- and foundation-funded projects examining genetics, lifestyle factors, and neighborhood characteristics in relation to cancer risk. Dr. Cheng has developed an extensive research program focused on racial/ethnic differences in cancer risk and leads population-based cancer surveillance studies that document variations in cancer incidence and mortality patterns across diverse racial and ethnic groups. University of California, Davis, BS, 1990–1994, Physiology Yale University, MPH, 1999–2001, Chronic Disease Epidemiology University of Southern California, PhD, 2001–2005, Epidemiology University of California, San Francisco, Postdoc, 2006–2008, Genetic and Molecular Epidemiology Dr. Cheng's research spans multiple disciplines within cancer epidemiology, with particular emphasis on understanding how environmental exposures, genetic factors, and social determinants interact to influence cancer risk and outcomes across different racial and ethnic populations. Her work frequently examines the impact of air pollution, endocrine-disrupting chemicals, and neighborhood characteristics on cancer development and survival. She has made significant contributions to understanding cancer disparities among Asian American, Native Hawaiian, and Pacific Islander populations, bringing attention to the unique cancer risks and outcomes within these understudied groups. Her research often leverages the Multiethnic Cohort Study, one of the largest prospective studies of cancer incidence and mortality across diverse racial/ethnic populations. Analysis of Dr. Cheng's recent publications reveals a consistent focus on environmental and social determinants of cancer risk across multiple organ sites. Her work demonstrates a sophisticated integration of epidemiological methods with environmental exposure assessment, genetic analysis, and health disparities research. Many of her studies examine the intersection of environmental exposures and racial/ethnic disparities in cancer outcomes, particularly regarding breast cancer, lung cancer, and other malignancies. She has published extensively on the impact of air pollution on cancer risk and survival, as well as the effects of endocrine-disrupting chemicals like bisphenol A, parabens, and phthalates. American Association for Cancer Research Scholar-in-Training Award (2007) National Institutes of Health Loan Repayment Award (2007) National Institutes of Health Loan Repayment Renewal Award (2009) American Association for Cancer Research Faculty Scholar Award (2011) National Institutes of Health Loan Repayment Renewal Award (2011) National Institutes of Health Loan Repayment Renewal Award (2013) American Journal of Epidemiology/Society of Epidemiology Research Top 10 manuscripts (2014) Cancer Prevention Institute of California Mentoring Award (2015) American Society of Human Genetics Top poster As Principal Investigator of multiple NIH-funded projects, Dr. Cheng oversees substantial research grants focused on cancer epidemiology and health disparities. Her work often involves large interdisciplinary collaborations with researchers across multiple institutions, including the Multiethnic Cohort Study which follows over 200,000 participants from diverse racial/ethnic backgrounds. She has demonstrated leadership in mentoring junior researchers, particularly those from underrepresented backgrounds in science, as evidenced by her Cancer Prevention Institute of California Mentoring Award. Her research program integrates data from cancer registries, electronic health records, and geospatial information to provide comprehensive insights into cancer patterns and risk factors. Dr. Cheng's research is closely connected to the UCSF Helen Diller Family Comprehensive Cancer Center and leverages collaborations with Lawrence Berkeley National Laboratory, which provides advanced technological resources for cancer research. Her work benefits from access to extensive cohort data, sophisticated exposure assessment methods, and interdisciplinary expertise in genetics, environmental science, and computational biology available through these institutional partnerships. She frequently collaborates with researchers studying the genetic and environmental determinants of cancer across multiple organ systems, contributing to a more comprehensive understanding of cancer etiology and prevention strategies.

John D. Osborneمشاهده پروفایل

استادیار

• Natural Language Processing
• Bioinformatics
• Biomedical Informatics
• +۳ مورد دیگر

Dr. John D. Osborne is an Assistant Professor in the Department of Computer Science at the University of Alabama at Birmingham (UAB), with a secondary appointment in the same department. He specializes in Natural Language Processing (NLP), particularly in biomedical text analysis and clinical phenotyping. His work focuses on applications such as drug repurposing and identifying patient cohorts for research and clinical care. Dr. Osborne’s research interests include the relationship between genotype and phenotype, microbial bioinformatics, and developing NLP systems to support healthcare. He previously contributed to the Disease Ontology at Northwestern University and worked at the CDC and UAB’s Viral Bioinformatics Resource Center. His lab at UAB develops integrated registry systems to identify patients with conditions like reportable cancers, multiple myeloma, delirium, and opiate use disorder. No scientific awards or specific grants are mentioned in the provided text.

• Cancer Genomics
• Precision Medicine
• Colorectal Cancer Research
• +۵ مورد دیگر

Tobias Sjöblom serves as Professor and Head of Department at Uppsala University's Department of Immunology, Genetics and Pathology, where he leads the Cancer Precision Medicine research program. His work bridges clinical oncology and molecular biology, with particular focus on translating genomic findings into clinical applications for cancer patients. His research interests center on cancer genomics, precision medicine, and molecular diagnostics, with extensive work on colorectal cancer biology and treatment. Sjöblom's laboratory investigates how genetic variations influence cancer development, progression, and response to therapy, particularly focusing on pharmacogenomic biomarkers that can guide personalized treatment decisions. His work spans from basic molecular mechanisms to clinical applications, with strong emphasis on translating research findings into clinical practice. Analyzing his recent publication record reveals a clear trajectory toward precision oncology applications, with increasing focus on liquid biopsy technologies, AI-assisted diagnostics, and biomarker-driven treatment strategies. His research demonstrates a consistent pattern of investigating how specific genetic alterations (particularly in NAT2, CYP2D6, and other metabolic enzymes) can be leveraged for targeted cancer therapies. The interdisciplinary nature of his work is evident in collaborations spanning molecular biology, clinical oncology, bioinformatics, and medical imaging. Sjöblom has established significant research infrastructure through initiatives like the U-CAN biobank, creating valuable resources for cancer research across Sweden. His leadership extends to developing novel methodologies for cancer genomics and diagnostics, including advanced techniques for mutation detection and tissue analysis. His laboratory maintains strong clinical connections, working closely with oncologists and surgeons to ensure research questions address real clinical challenges. This translational approach has resulted in numerous publications in high-impact journals including Nature, Science, and Cell Death and Disease, demonstrating the significance and quality of his contributions to cancer research.

Elizabeth Lemmonمشاهده پروفایل

پژوهشگر ارشد

• Health Economics
• Applied Econometrics
• Aging Economics
• +۳ مورد دیگر

Elizabeth Lemmon is a Research Fellow within the Health Economics Group of the Edinburgh Clinical Trials Unit at the Usher Institute, University of Edinburgh. Her work focuses on applying econometric methods to healthcare and social care data, particularly in the context of aging populations and long-term care provision. PhD in Economics, University of Stirling (2019) MSc in Economics, University of Edinburgh (2014) BA Hons in Economics, University of Stirling (2013) Her research spans applied econometric analysis of survey and administrative data, economic aspects of aging, unpaid care dynamics, long-term care provision, health and care resource utilization at end-of-life, and policy implications derived from data-driven insights. A key component of her work involves leveraging Scottish and English national health data repositories to evaluate cancer care costs, screening efficiency, and treatment outcomes. Recent publications highlight her expertise in analyzing colorectal cancer economics, end-of-life hospital cost trajectories, and long-term care vulnerabilities during pandemics. She has contributed to the development of the national CORECT-R data repository and has explored international comparisons of care home mortality during the COVID-19 crisis. Elizabeth is actively engaged in public and patient involvement initiatives, ensuring her research informs both policy and clinical practice through the integration of administrative datasets.

Franz Lennard Ricklefsمشاهده پروفایل

استاد

• Neurosurgery
• Neuro-oncology
• Molecular Neurobiology
• +۵ مورد دیگر

Prof. Dr. med. Franz Lennard Ricklefs is a Senior Physician and Head of the Working Group at the Department of Neurosurgery, University of Hamburg Faculty of Medicine. He is a Medical Specialist in Neurosurgery with cross-disciplinary expertise in neuro-oncology, molecular pathology, and extracellular vesicle research. Affiliations: University Medical Center Hamburg-Eppendorf (UKE), European Liquid Biopsy Society (ELBS), International Consortium on Meningiomas (ICOM) Research Interests: His work focuses on neurosurgical oncology, particularly glioblastoma and meningioma pathobiology. He investigates DNA methylation patterns, extracellular vesicle biomarkers, and liquid biopsy implementation in clinical neuro-oncology. Additional interests include surgical outcomes for epilepsy and aneurysm management. Article Trends: Over the last decade, Dr. Ricklefs has published extensively on: Extracellular vesicle applications as liquid biopsy markers DNA methylation subclasses for glioblastoma and meningioma Multicenter surgical outcome benchmarking Immune evasion mechanisms in neuro-oncology Technological innovations in neurosurgical visualization Molecular characterization of rare CNS tumors Professional Contributions: He co-authored the MISEV2023 guidelines for extracellular vesicle studies and participates in international consensus reviews for meningioma classification. His collaborations span institutions across Europe and North America.

Rafael Pereraمشاهده پروفایل

استاد

• Medical Statistics
• Primary Care Health Sciences
• Monitoring of Long-Term Conditions
• +۶ مورد دیگر

Rafael Perera is a Professor of Medical Statistics at the Nuffield Department of Primary Care Health Sciences (NDPCHS), University of Oxford, where he has been since 2002. He holds leadership roles as Director of the Statistics Group and Director of Graduate Studies , overseeing academic leadership and methodological research. He is also a Statistical Editor of BMJ and BMJ Medicine , and a fellow at St Hugh’s College Oxford . Education : DPhil, MSc, MA Rafael’s research focuses on monitoring for managing long-term conditions (e.g., Type 2 diabetes, hypertension) and complex multimorbidity phenotypes . His work includes impact of extreme temperatures on health , meta-analysis methods , and methodology for infectious diseases . He leads large methodological groups and has been a PI on NIHR-funded infrastructure programs (BRC, ARC, MIC). Recent publications highlight his expertise in clinical prediction models , digital health interventions , and diagnostic test evaluation . His grants span applied research , global health transformation , and ageing research . Scientific Awards : National and international recognition for methodology development in clinical trials (NIHR Progress Report 2008/09) Rafael supervises DPhil and MSc students and leads a fully accredited Clinical Trials Unit . His editorial and policy influence extends to healthcare policy panels and the Centre for Evidence-Based Medicine as Director of Research Methodologies.

Simon Crouchمشاهده پروفایل

پژوهشگر ارشد

• Statistical Modeling
• Epidemiology
• Cancer Research
• +۶ مورد دیگر

Simon Crouch is a Senior Research Fellow in Biostatistics at the University of York's Health Sciences department. With a strong mathematical background from Cambridge and Warwick, he leads the analytics team within the Epidemiology and Cancer Statistics Group and works closely with the Haematological Malignancy Research Network (HMRN) and Cardiovascular Health team. His work focuses on statistical modeling of complex epidemiological data related to hematological malignancies. University of Cambridge: MA, MMath in Mathematics University of Warwick: PhD in Mathematics University of Lancaster: MSc in Medical Statistics Dr. Crouch specializes in the statistical modeling of complex epidemiological data, with particular focus on hematological malignancies. His research encompasses predictive modeling, event history analysis, and machine learning applications in cancer epidemiology. He has made significant contributions to understanding myelodysplastic syndromes, lymphoma classification, and survival analysis in blood cancers through population-based studies. His work often involves collaboration with international registries including the European Myelodysplastic Syndromes Registry (EUMDS) and the Haematological Malignancy Research Network. Analysis of his recent publications reveals a strong focus on myelodysplastic syndromes (MDS), with particular attention to risk stratification, survival analysis, and treatment outcomes. His work increasingly incorporates genomic and molecular data to refine disease classification and prediction models. The trend shows progression from purely statistical methodology development toward integrated translational research that combines clinical, genomic, and epidemiological data to improve patient outcomes. Extensive publication record with 113 research outputs including 66 articles, 21 patents, and numerous meeting abstracts Active participation in major international research consortia including MDS-RIGHT and ImmunAID Significant contributions to the development of statistical methodologies for cancer epidemiology Dr. Crouch actively supervises PhD students in mathematical and statistical modeling applied to cancer epidemiology, with particular interest in time-to-event models, complex longitudinal models, and simulation techniques. His research has been supported through multiple projects, including the European Myelodysplastic Syndromes Registry and the MDS-RIGHT project focused on facilitating informed decision-making in hemato-oncology. He contributes to the Advanced Health and Social Statistics module for postgraduate students at the University of York.

Andrew T Arndtمشاهده پروفایل

استادیار بالینی

• Thoracic Surgery
• Lung Cancer
• Chest Wall Tumors
• +۳ مورد دیگر

Andrew T Arndt, MD is a Clinical Assistant Professor in the Department of Surgery specializing in Thoracic Surgery at Northwestern University's Feinberg School of Medicine. Board certified by the American Board of Thoracic Surgery, he maintains clinical practice at Northwestern Medicine Central DuPage Hospital and holds active memberships in the Society of Thoracic Surgeons (2023-present) and American Board of Thoracic Surgery (2022-present). His research concentrates on advancing thoracic surgical oncology through investigations into lung cancer resection outcomes, chest wall tumor management, minimally invasive techniques, and pneumothorax recurrence factors. Current work emphasizes evidence-based risk stratification and surgical innovation to improve patient outcomes in complex thoracic pathologies. Recent publications demonstrate consistent focus on surgical registry analysis (2021), consensus development for thoracoscopic training (2021), systematic reviews of rare chest wall malignancies (2023), and identification of lifestyle-related recurrence risks (2021). This trajectory highlights growing contributions to thoracic surgical guidelines and evidence-based practice standards. Dr. Arndt serves as a consultant for Intuitive Surgical, Inc. (2024 disclosures) while maintaining active clinical and academic roles. No formal advisees or research grants are listed in current profile materials. Within Northwestern's Department of Surgery, he contributes to the Thoracic Surgery division's clinical and research missions, particularly in advancing minimally invasive approaches and multidisciplinary management of complex thoracic conditions through collaborative registry studies and consensus initiatives.

• Pharmaceutical Care
• Interdisciplinary Collaboration
• Patient-Centered Care
• +۵ مورد دیگر

Veerle Foulon serves as full professor and dean of the Faculty of Pharmaceutical Sciences at KU Leuven, Belgium. She leads the Unit Clinical Pharmacology and Pharmacotherapy within the Department of Pharmaceutical and Pharmacological Sciences. Her institutional leadership roles include membership in the University Council, Academic Council, and Special Academic Council as dean, alongside positions in the Board for Alumni Relations and Biomedical Sciences Group Management. Leuven Centre for Health Humanities Leuven Interdisciplinary Centre for Meaning and Lived Religion LC&Y - KU Leuven Institute for Child and Youth LIVO – KU Leuven Institute for Educational Research LKI - KU Leuven Cancer Institute Her research centers on pharmaceutical care, interdisciplinary collaboration, patient-centered care, and rational pharmacotherapy. Key focus areas include medication safety during pregnancy through the BELpREG registry, antimicrobial stewardship in Ethiopian healthcare settings, and person-centered medication optimization for elderly patients in nursing homes. She emphasizes real-world data collection and interdisciplinary approaches to address critical gaps in medication safety for vulnerable populations. Analysis of her recent publications reveals dominant themes in pregnancy medication safety (particularly via the BELpREG cohort), nursing home medication pathways, and antimicrobial resistance interventions. Her work consistently involves large-scale international collaborations across Europe and Ethiopia, addressing systemic challenges in pharmaceutical care through mixed-methods designs and registry-based studies. As principal investigator on major funded projects extending to 2028—including antimicrobial resistance initiatives in Ethiopia and pregnancy medication safety studies—she directs substantial research grants. Her leadership in interdisciplinary consortia drives innovation in medication optimization, though specific doctoral advisees are not documented in the provided materials. Current projects demonstrate strong translational focus with direct clinical implementation pathways. Embedded within multiple Leuven research institutes, she fosters cross-disciplinary collaborations through the BELpREG consortium and antimicrobial stewardship networks. Her work actively involves partnerships with Ethiopian tertiary hospitals, European pregnancy registries, and Belgian nursing home networks to develop and implement evidence-based pharmaceutical care models.